
    
      A total of 72 subjects were consented and screened, with 56 subjects (28 males and 28 female)
      being eligible to participate in the study. Fifty-six subjects with muscle/nerve pain were
      randomized at a ratio of 1:1 to one of two treatment groups. To evaluate primary and
      secondary objectives, study assessments were conducted at Baseline, and Day 28 Â± 2. The
      Individualized Neuromuscular Quality of Life Questionnaire (INQoL), Symptom Impact
      Questionnaire (SQIR), Mini-Mental State Examination (MMSE) were completed by participants to
      assess physical function, pain, fatigue/energy and cognitive function.
    
  